Mithridion, Inc. announced results from a Phase 1 study of MCD-386, its lead drug candidate for Alzheimer’s disease (AD). This study was a randomized, double-blind, placebo-controlled, ascending single dose trial conducted in 24 healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of MCD-386. Serum drug concentrations were successfully measured in the 18 subjects receiving MCD-386; enabling pharmacokinetic parameters to be determined.
MCD-386 is an M1 selective muscarinic agonist with potential for improving memory and cognition symptoms, and for disease-modifying effects (or stopping disease progression) in AD.
For information call (608) 443-2432 or visit www.mithridion.com.